“These results are pivotal for EMulate as we continue to develop, optimize and expand our technology’s use and value,” stated Chris Rivera, EMulate’s President and CEO. “These data in glioblastoma (GBM) are very encouraging and provide further validation supporting multiple animal models and veterinary studies that have indicated potential clinical benefit(s).”

“This publication is the culmination of work done at multiple clinical sites in the United States and represents a significant new technology that may alter and/or add to the treatment paradigm in glioblastoma and other cancer indications,” stated Dr. Santosh Kesari, MD, PhD, at the Providence Neuro-Oncology Program and Saint John’s Cancer Institute, Santa Monica, CA.

Mr. Rivera also stated, “EMulate is also seeking to initiate a pivotal Phase III study in newly diagnosed GBM in the near future and is also seeking FDA approval for treatment of diffuse midline gliomas, including diffuse intrinsic pontine gliomas, via the Humanitarian Device Exemption pathway later this year based on encouraging compassionate use results in patients, as well as encouraging pre-clinical study results in DIPG animal models. We are also planning to initiate a pivotal Phase III study in these indications in early 2024.”

About EMulate Therapeutics, Inc.

EMulate Therapeutics is a clinical stage company, reshaping the therapeutic treatment landscape with digital medicines using its proprietary radio frequency energy technology (RFE) targeted at the low and ultra-low ends of the RFE spectrum (ulRFE®) to emulate the effects of drugs and other therapies in treating patients, without the administration of physical drug substances themselves. The use of ulRFE has been shown to be safe to date and the potential therapeutic benefits, specifically targeted at patients’ underlying conditions, continue to be evaluated in multiple studies. This versatile, non-invasive platform technology may provide a solution for patients with cancer, acute and chronic pain, mental health disorders and other serious conditions. The company has generated encouraging human data from patients afflicted with glioblastoma and diffuse midline glioma and is preparing for pivotal (phase III) studies in each indication. It has also generated encouraging preclinical studies in pain management and mental health models and is preparing for initial human clinical trials in each area. In addition, positive data have been generated independently in animal health (positive cancer results in over 20 different solid tumor types in canines (pets)), as well as in bio-agriculture models. EMulate Therapeutics is the licensor of its proprietary technology to Hapbee Technologies, Inc. (HAPB: TSVX). Hapbee is a commercial stage consumer wellness-wearable technology company spun out from EMulate in 2019. EMulate is the largest independent shareholder in Hapbee and recipient of quarterly royalties from net sales.

About our ulRFE Device

EMulate Therapeutics (EMTx) has developed a non-sterile, non-invasive, non-thermal, non-ionizing, battery-powered, portable investigational medical device that uses low to ultra-low level (DC-22kHz) frequencies to deliver specific electromagnetic fields to produce specific biological effects, including, e.g., increasing tubulin polymerization in numerous cancer models, emulating the effects of psychedelic drugs in mental health models and reducing of pain sensations, among others. The system emits a low power magnetic field (< 100 mG) that can be applied locally or globally, dependent on the type of therapeutic effect sought. The EMTX signals are stored as WAV files on the device and emitted via a cable to the attached antenna unit.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This press release contains “forward-looking statements.” Forward-looking statements discuss matters that are not historical facts. Because they discuss future events or conditions, forward-looking statements may include words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “could,” “should,” “would,” “plan,” “project,” “forecast,” and “potential,” the negatives thereof or similar expressions. Forward-looking statements speak only as of the date made, are based on various underlying assumptions and current expectations about the future and are not guarantees of future performance. While we believe these assumptions and expectations are reasonable, are made in good faith and have a reasonable basis, assumed facts or bases almost always vary from actual results, and the differences between assumed facts or expectations and actual results can be material, depending on the circumstances. Such statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, level of activity, performance or achievement to be materially different from the results of operations or plans expressed or implied by such forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates, or to regard them as representations that the results or conditions described in such statements will occur or that our objectives and plans will be achieved.

Except to the extent required by law, we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, a change in events, conditions, circumstances or assumptions underlying such statements, or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230718614410/en/